206 related articles for article (PubMed ID: 37907848)
1. Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports.
Mizuno T; Kanouchi T; Tamura Y; Hirata K; Emoto R; Suzuki T; Kashimada K; Morio T
BMC Neurol; 2023 Oct; 23(1):392. PubMed ID: 37907848
[TBL] [Abstract][Full Text] [Related]
2. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
[TBL] [Abstract][Full Text] [Related]
3. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
Bitetti I; Lanzara V; Margiotta G; Varone A
Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
[TBL] [Abstract][Full Text] [Related]
4. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
[TBL] [Abstract][Full Text] [Related]
5. Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1.
Nanri D; Yuge K; Goto K; Kimura T; Yae Y; Mizuochi T; Sato R; Itonaga T; Maeda T; Yamashita Y
Kurume Med J; 2024 May; 69(3.4):255-259. PubMed ID: 38233181
[TBL] [Abstract][Full Text] [Related]
6. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
[TBL] [Abstract][Full Text] [Related]
7. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.
Funato M; Kino A; Iwata R; Yumioka M; Yamashita K; Urui C; Uno R; Kondo E; Morioka E; Ogawa Y; Kawamura A; Kusukawa T; Minatsu H
Brain Dev; 2024 Jan; 46(1):62-67. PubMed ID: 37657961
[TBL] [Abstract][Full Text] [Related]
8. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
[TBL] [Abstract][Full Text] [Related]
9. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
[No Abstract] [Full Text] [Related]
10. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.
Erdos J; Wild C
Eur J Paediatr Neurol; 2022 Jul; 39():1-10. PubMed ID: 35533607
[TBL] [Abstract][Full Text] [Related]
11. Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen.
Richard M; Barrois R; Desguerre I; Deladrière E; Leloup-Germa V; Barnerias C; Gitiaux C
Arch Pediatr; 2024 Jan; 31(1):26-31. PubMed ID: 37989659
[TBL] [Abstract][Full Text] [Related]
12. Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study.
Stettner GM; Hasselmann O; Tscherter A; Galiart E; Jacquier D; Klein A
BMC Neurol; 2023 Feb; 23(1):88. PubMed ID: 36855136
[TBL] [Abstract][Full Text] [Related]
13. Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
Ueda Y; Egawa K; Kawamura K; Ochi N; Goto T; Kimura S; Narugami M; Nakakubo S; Nakajima M; Manabe A; Shiraishi H
Brain Dev; 2024 Mar; 46(3):149-153. PubMed ID: 38103972
[TBL] [Abstract][Full Text] [Related]
14. Neurophysiological Characteristics in Type II and Type III 5q Spinal Muscular Atrophy Patients: Impact of Nusinersen Treatment.
Li D; Sun N; Xiang L; Liu J; Wang X; Yang L; Huang S
Drug Des Devel Ther; 2024; 18():953-965. PubMed ID: 38562520
[TBL] [Abstract][Full Text] [Related]
15. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry.
Servais L; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Proud CM; Shieh PB; Tizzano EF; Quijano-Roy S; Desguerre I; Saito K; Faulkner E; Benguerba KM; Raju D; LaMarca N; Sun R; Anderson FA; Finkel RS
J Neuromuscul Dis; 2024; 11(2):425-442. PubMed ID: 38250783
[TBL] [Abstract][Full Text] [Related]
16. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
[TBL] [Abstract][Full Text] [Related]
17. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
18. Combination molecular therapies for type 1 spinal muscular atrophy.
Harada Y; Rao VK; Arya K; Kuntz NL; DiDonato CJ; Napchan-Pomerantz G; Agarwal A; Stefans V; Katsuno M; Veerapandiyan A
Muscle Nerve; 2020 Oct; 62(4):550-554. PubMed ID: 32710634
[TBL] [Abstract][Full Text] [Related]
19. Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy.
Blair HA
CNS Drugs; 2022 Sep; 36(9):995-1005. PubMed ID: 35960489
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil.
Fernandes BD; D'Athayde Rodrigues F; Cardoso Cirilo HN; Borges SS; Krug BC; Probst LF; Zimmermann I
Value Health Reg Issues; 2024 Mar; 40():108-117. PubMed ID: 38181723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
